목적: Patients with HPV-related oropharyngeal cancer (OPC) have better prognosis in terms of response and survival. p16 has been recently thought to be a proper surrogate marker for HPV. However there are some controversies in that role for the head and neck cancer other than OPC. Therefore the author was to study about the role of p16 in the prognostic significance of the treatment of induction chemoradiotherapy for advanced hypopharyngeal squamous cell carcinoma (HPSCC). 방법:Patients who treated with at least 2 cycles of induction chemotherapy followed by concurrent chemoradiotherapy for locally advanced HPSCC were reviewed. Immunohistochemical stain for p16 was done in paraffin embedded tumor tissue. The author also investigated p53 expression that has well known a biomarker to predict the chemotherapy response. The staining results were analyzed to check the relation with the chemotherapy response and survival outcomes. 결과:Forty-five patients were enrolled for this study and most of them performed induction chemotherapy with docetaxel, cisplatin and 5-FU. After induction chemotherapy, 17 patients (37.8%) showed complete response and 28 patients (62.2%) showed partial response. There were 11 patients (24.4%) with p16 positive and 30 patients (66.7%) with p53 positive. There was no significant difference in chemotherapy response, overall survival or progression free survival between groups with p16 positive and negative stain. Low p53 expression and chemotherapy response were not associated with each other. High p16 expression did not correlate with low p53 expression. 결론:In this study, p16 was not found to predict the chemotherapy response for HPSCC. High p16 expression did not correlate with the survival for patients with HPSCC.